Ainos Expands AI Nose Platform with July Study to Differentiate COPD and Heart Failure
AIMD•Ainos will begin a one-year research program with National Taiwan University on July 1, 2026, evaluating whether AI-analyzed breath patterns can distinguish acute COPD exacerbations from acute decompensated heart failure. This study expands its AI Nose platform into patient-level breath intelligence and enriches datasets for its Smell Language Model.
1. Research Program Launch
Ainos will launch a one-year research program with National Taiwan University starting July 1, 2026, to evaluate whether AI-analyzed breath patterns can distinguish acute COPD exacerbations from acute decompensated heart failure in patients presenting with shortness of breath.
2. AI Nose Platform Expansion
The study extends the AI Nose platform’s Smell ID capabilities from environmental sensing into patient-level breath analysis, digitizing breath-related scent patterns into structured, machine-readable data for diagnostic use.
3. Smell Language Model Impact
By integrating real-world breath data, the program is expected to broaden the datasets supporting Ainos’ Smell Language Model, enhancing its ability to learn, classify and contextualize complex scent signatures across healthcare applications.
4. CEO Commentary
Eddy Tsai, Chairman and CEO, said applying AI Nose to emergency-care scenarios addresses a high-value diagnostic challenge where rapid and accurate differentiation can directly impact patient outcomes.
